JP2008273875A - Agent for suppressing increase of expression of stem cell factor - Google Patents

Agent for suppressing increase of expression of stem cell factor Download PDF

Info

Publication number
JP2008273875A
JP2008273875A JP2007119579A JP2007119579A JP2008273875A JP 2008273875 A JP2008273875 A JP 2008273875A JP 2007119579 A JP2007119579 A JP 2007119579A JP 2007119579 A JP2007119579 A JP 2007119579A JP 2008273875 A JP2008273875 A JP 2008273875A
Authority
JP
Japan
Prior art keywords
extract
scf
agent
expression
suppressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007119579A
Other languages
Japanese (ja)
Other versions
JP5137457B2 (en
Inventor
Keiko Doi
圭子 土肥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maruzen Pharmaceutical Co Ltd
Original Assignee
Maruzen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maruzen Pharmaceutical Co Ltd filed Critical Maruzen Pharmaceutical Co Ltd
Priority to JP2007119579A priority Critical patent/JP5137457B2/en
Publication of JP2008273875A publication Critical patent/JP2008273875A/en
Application granted granted Critical
Publication of JP5137457B2 publication Critical patent/JP5137457B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

<P>PROBLEM TO BE SOLVED: To provide an agent for suppressing the increase of expression of a stem cell factor (SCF) by finding a substance having an action to suppress the increase of expression of a stem cell factor (SCF) from natural materials having high safety and using the substance as an active component of the agent, and to provide a prevention or treatment agent containing the suppressing agent. <P>SOLUTION: The agent for suppressing the increase of expression of SCF comprises one or more vegetable extracts selected from the extracts of Averrhoa carambola L., Glychyrrhiza glabra, Rubus ellipticus, Eriobotrya japonica Lindley, Machilus odoratissima, Melissa officinalis, Alpinia spesiosa, Coix lachrymal-jobi L., Ligusticum wallichii Franch., Prunus persica seed and Gentiana Lutea, as an active component, and the preventing or treating agent contains the suppressing agent. The suppressing agent suppresses the abnormal growth of myeloblast and is useful for the prevention or treatment of myelodysplastic syndromes, acute myelocytic leukemia, etc. The suppressing agent is also useful as a cosmetic effective for the prevention or suppression of pigmentation, spot, freckle, etc., after sunburn by suppressing the growth of pigment cell and the excessive production of melanin in the skin. <P>COPYRIGHT: (C)2009,JPO&INPIT

Description

本発明は、幹細胞増殖因子発現上昇抑制剤に関する。   The present invention relates to a stem cell growth factor expression increase inhibitor.

シミ、ソバカス、日焼け後の皮膚色素沈着症等は、皮膚内に存在する色素細胞(メラノサイト)の活性化によりメラニン産生が著しく亢進した結果として生ずるものであり、多くの女性において肌の悩みの一つになっている。従来、美白効果を有するものとして種々の治療薬、皮膚外用剤、化粧料等が知られている。例えば、チロシナーゼ活性を阻害してメラニン産生を抑制するものとして、コロイド硫黄やグルタチオンに代表される硫黄化合物が用いられている。また、産生したメラニンを淡色漂白化するものとして、アスコルビン酸類、過酸化水素、ハイドロキノン、カテコール等が用いられている。   Spots, buckwheat, skin pigmentation after sunburn, etc. occur as a result of markedly increased melanin production due to activation of pigment cells (melanocytes) present in the skin. It is connected. Conventionally, various therapeutic agents, external preparations for skin, cosmetics and the like are known as having a whitening effect. For example, as a compound that inhibits tyrosinase activity and suppresses melanin production, sulfur compounds represented by colloidal sulfur and glutathione are used. In addition, ascorbic acids, hydrogen peroxide, hydroquinone, catechol and the like are used to lightly bleach the produced melanin.

しかしながら、アスコルビン酸類は、含水化粧料のような水分を多く含むものに含有せしめると酸化されやいために不安定であり、化粧料の変色の原因となってしまう。また、過酸化水素水は、保存上の安定性及び使用上の安全性に問題がある。さらに、グルタチオン及びコロイド硫黄等の硫黄化合物は、著しい異臭を放つ点で問題がある。さらにまた、ハイドロキノン及びカテコールは、皮膚刺激性及びアレルギー性等を有し、使用上の安全性に問題がある。したがって、これらの美白成分を化粧料等の製品に使用することは制約されており、未だ十分に満足できる美白成分は知られておらず、より優れた美白剤の開発が所望されている。   However, ascorbic acids are unstable because they are easily oxidized when they are contained in water-rich cosmetics such as water-containing cosmetics, and cause discoloration of the cosmetics. Further, the hydrogen peroxide solution has problems in storage stability and safety in use. Furthermore, sulfur compounds such as glutathione and colloidal sulfur have a problem in that they emit a significant off-flavor. Furthermore, hydroquinone and catechol have skin irritation and allergic properties and have a problem in safety in use. Therefore, the use of these whitening ingredients in products such as cosmetics is restricted, and no whitening ingredients that are sufficiently satisfactory are yet known, and the development of better whitening agents is desired.

幹細胞増殖因子(Stem Cell Factor,SCF)は、Must Cell Growth Factor、C-Kit Ligand、Steel Factor等とも呼ばれ、角化細胞、線維芽細胞、血管内皮細胞、骨髄ストローマ細胞等から産生されるタンパク質である。SCFは、多能性造血幹細胞、生殖細胞、肥満細胞、巨核球系前駆細胞、顆粒球・マクロファージ系前駆細胞、色素細胞等の増殖や分化を促進する作用を有することが知られている。また、SCFは、シミ部位や紫外線照射等によって発現が亢進することが知られている(非特許文献1参照)。   Stem Cell Factor (SCF), also called Must Cell Growth Factor, C-Kit Ligand, Steel Factor, etc., is a protein produced from keratinocytes, fibroblasts, vascular endothelial cells, bone marrow stromal cells, etc. It is. SCF is known to have an action of promoting proliferation and differentiation of pluripotent hematopoietic stem cells, germ cells, mast cells, megakaryocyte progenitor cells, granulocyte / macrophage progenitor cells, pigment cells and the like. Moreover, it is known that the expression of SCF is enhanced by a spot site, ultraviolet irradiation or the like (see Non-Patent Document 1).

SCFとしては、273のアミノ酸残基からなる膜結合型SCFと、タンパク質分解酵素の作用により切断され、膜から遊離する分泌型SCFとが知られている。膜結合型SCFは、角化細胞等に結合したまま色素細胞のSCFレセプターに結合し、色素細胞の増殖を促進する。分泌型SCFは、その結合部位にて切断され、細胞膜から遊離し、色素細胞のSCFレセプターに結合することによって、色素細胞の増殖を促進する。   As SCF, a membrane-bound SCF composed of 273 amino acid residues and a secreted SCF that is cleaved by the action of a proteolytic enzyme and released from the membrane are known. Membrane-bound SCF binds to the SCF receptor of the pigment cell while bound to keratinocytes and promotes the proliferation of the pigment cell. Secreted SCF is cleaved at its binding site, released from the cell membrane, and promotes proliferation of pigment cells by binding to SCF receptors of pigment cells.

また、SCFは、急性骨髄性白血病患者において、インターロイキン−3(Interleukin-3,IL−3)や顆粒球マクロファージコロニー刺激因子(Granulocyte Macrophage Colony Stimulating Factor ,GM−CSF)の共存下で骨髄芽球の増殖を促進することが知られている(非特許文献2参照)。   In addition, SCF is a myeloblast in the presence of interleukin-3 (IL-3) and granulocyte macrophage colony stimulating factor (GM-CSF) in patients with acute myeloid leukemia. It is known to promote the growth of selenium (see Non-Patent Document 2).

そのため、SCFの異常産生は、色素細胞の異常増殖につながり、メラニン産生を亢進させ、シミ、ソバカス、くすみ等の原因となると考えられる。また、SCFの異常産生は、骨髄芽球の異常増殖につながり、それにより骨髄異形成症候群、急性骨髄性白血病(AML)等の疾患を引き起こすものと考えられる。   Therefore, abnormal production of SCF is thought to lead to abnormal growth of pigment cells, increase melanin production, and cause stains, buckwheat, dullness, and the like. Abnormal production of SCF is thought to lead to abnormal growth of myeloblasts, thereby causing diseases such as myelodysplastic syndrome and acute myeloid leukemia (AML).

したがって、SCFの発現上昇を抑制することは、色素細胞の増殖を抑制し、皮膚におけるメラニンの過剰産生を抑制し、日焼け後の色素沈着、シミ、ソバカス等の予防又は抑制に有用であると考えられる。また、SCFの発現上昇を抑制することは、骨髄芽球の異常増殖を抑制し、骨髄異形成症候群、急性骨髄性白血病等の予防又は治療に有用であると考えられる。
Hachiya A et al., J. Invest. Dermatol., No.116, 2001, p.578-586 Virginia C. Broudy et al., Blood, Vol.80, No.1, 1992, p.60-67
Therefore, suppressing the increase in SCF expression suppresses the proliferation of pigment cells, suppresses the excessive production of melanin in the skin, and is considered useful for the prevention or suppression of pigmentation, sun spots, buckwheat, etc. after sunburn. It is done. Further, suppressing the increase in the expression of SCF suppresses abnormal proliferation of myeloblasts and is considered useful for the prevention or treatment of myelodysplastic syndrome, acute myeloid leukemia and the like.
Hachiya A et al., J. Invest. Dermatol., No.116, 2001, p.578-586 Virginia C. Broudy et al., Blood, Vol.80, No.1, 1992, p.60-67

本発明は、安全性の高い天然物の中からSCF発現上昇抑制作用を有するものを見出し、それを有効成分とする幹細胞増殖因子(SCF)発現上昇抑制剤を提供することを目的とする。   An object of the present invention is to provide a highly safe natural product having an inhibitory effect on the increase in SCF expression, and to provide an agent for suppressing an increase in the expression of stem cell growth factor (SCF) containing the active ingredient as an active ingredient.

上記課題を解決するために、本発明の幹細胞増殖因子(SCF)発現上昇抑制剤は、五斂子抽出物、甘草葉部抽出物、オニイチゴ抽出物、ビワ抽出物、マチルス抽出物、メリッサ抽出物、月桃抽出物、ハトムギ抽出物、センキュウ抽出物、トウニン抽出物及びゲンチアナ抽出物からなる群より選ばれる1種又は2種以上の植物抽出物を有効成分として含有することを特徴とする。   In order to solve the above-mentioned problems, the stem cell growth factor (SCF) expression increase inhibitor of the present invention is a pentagonal extract, licorice leaf extract, oni strawberry extract, loquat extract, matylus extract, melissa extract. It is characterized by containing, as an active ingredient, one or more plant extracts selected from the group consisting of moon peach extract, pearl barley extract, nematode extract, tonin extract and gentian extract.

また、本発明の幹細胞増殖因子(SCF)の発現上昇に起因する疾患の予防・治療剤は、五斂子抽出物、甘草葉部抽出物、オニイチゴ抽出物、ビワ抽出物、マチルス抽出物、メリッサ抽出物、月桃抽出物、ハトムギ抽出物、センキュウ抽出物、トウニン抽出物及びゲンチアナ抽出物からなる群より選ばれる1種又は2種以上の植物抽出物を有効成分として含有することを特徴とする。   In addition, the preventive / therapeutic agent for diseases caused by the increased expression of stem cell growth factor (SCF) of the present invention is a quince extract, licorice leaf extract, oni strawberry extract, loquat extract, matylus extract, melissa One or more plant extracts selected from the group consisting of an extract, moon peach extract, pearl barley extract, nematode extract, tonin extract and gentian extract are contained as active ingredients .

本発明によれば、五斂子抽出物、甘草葉部抽出物、オニイチゴ抽出物、ビワ抽出物、マチルス抽出物、メリッサ抽出物、月桃抽出物、ハトムギ抽出物、センキュウ抽出物、トウニン抽出物及びゲンチアナ抽出物からなる群より選ばれる1種又は2種以上の植物抽出物を有効成分として含有し、安全性に優れた幹細胞増殖因子(SCF)発現上昇抑制剤及び幹細胞増殖因子(SCF)の発現上昇に起因する疾患の予防・治療剤を提供することができる。   According to the present invention, quince extract, licorice leaf extract, oni strawberry extract, loquat extract, matylus extract, melissa extract, moon peach extract, pearl barley extract, nematode extract, tonin extract And one or more plant extracts selected from the group consisting of gentian extracts as active ingredients, and an excellent inhibitor of stem cell growth factor (SCF) expression increase and stem cell growth factor (SCF) A prophylactic / therapeutic agent for diseases caused by increased expression can be provided.

以下、本発明について詳細に説明する。
〔幹細胞増殖因子発現上昇抑制剤〕
本発明の幹細胞増殖因子(以下「SCF」という。)発現上昇抑制剤は、五斂子抽出物、甘草葉部抽出物、オニイチゴ抽出物、ビワ抽出物、マチルス抽出物、メリッサ抽出物、月桃抽出物、ハトムギ抽出物、センキュウ抽出物、トウニン抽出物及びゲンチアナ抽出物からなる群より選ばれる1種又は2種以上の植物抽出物を有効成分として含有する。
Hereinafter, the present invention will be described in detail.
[Suppressor of stem cell growth factor expression increase]
The stem cell growth factor (hereinafter referred to as “SCF”) expression-inhibiting agent of the present invention includes five coconut extracts, licorice leaf extract, oni strawberry extract, loquat extract, matylus extract, melissa extract, moon peach One or two or more kinds of plant extracts selected from the group consisting of an extract, pearl barley extract, sensu extract, tonin extract and gentian extract are contained as active ingredients.

ここで、本発明において「抽出物」には、上記植物を抽出原料として得られる抽出液、当該抽出液の希釈液若しくは濃縮液、当該抽出液を乾燥して得られる乾燥物、又はこれらの粗精製物若しくは精製物のいずれもが含まれる。   Here, in the present invention, “extract” refers to an extract obtained from the above plant as an extraction raw material, a diluted or concentrated solution of the extract, a dried product obtained by drying the extract, or a crude product thereof. Both purified products and purified products are included.

本発明において使用する抽出原料は、五斂子、甘草葉部、オニイチゴ、ビワ、マチルス、メリッサ、月桃、ハトムギ、センキュウ、トウニン及びゲンチアナである。2種以上の植物を抽出原料として用いる場合、上記植物を任意に組み合わせて使用することができる。   The extraction raw materials used in the present invention are pentagon, licorice leaf part, oni strawberry, loquat, matils, melissa, moon peach, pearl barley, senkyu, tonin and gentian. When using two or more kinds of plants as an extraction raw material, the above plants can be used in any combination.

五斂子(学名:Averrhoa carambola L.)は、カタバミ科ゴレンシ属に属し、新鮮な果実は食用にされる。五斂子は、中国では紀元前から文献に記載され、その果実は断面が星形であることからスターフルーツとも呼ばれている。五斂子は、沖縄、中国東南部や雲南その他熱帯各地で栽培されており、これらの地域から容易に入手することができる。抽出原料として使用し得る部位としては、例えば、葉部、幹部、地上部、花部、果実部、種子部、根部、全草又はこれらの部位の混合物等が挙げられるが、好ましくは葉部である。   Goshiko (scientific name: Averrhoa carambola L.) belongs to the genus Carenaceae, and fresh fruits are edible. Goshiko has been described in literature in China since the BC, and its fruit is also called a star fruit because of its star-shaped cross section. Gosho is cultivated in Okinawa, southeastern China, Yunnan and other tropical regions, and can be easily obtained from these regions. Examples of the part that can be used as an extraction raw material include a leaf part, a stem part, an above-ground part, a flower part, a fruit part, a seed part, a root part, a whole plant, or a mixture of these parts. is there.

甘草は、マメ科カンゾウ属に属し、古代より薬用又は甘味料の原料として利用されている有用植物である。特に甘草の根部には、グリチルリチン、その他有用成分が含有されていることが確認されているが、これらの有用成分は甘草の葉部には含有されていない。これに対して、本発明者によって初めて確認されたSCF発現上昇抑制作用を有する成分は、甘草の葉部に含有されている。   Licorice belongs to the genus Lizoaceae and is a useful plant that has been used as a raw material for medicinal or sweeteners since ancient times. In particular, it has been confirmed that the root part of licorice contains glycyrrhizin and other useful ingredients, but these useful ingredients are not contained in the leaves of licorice. On the other hand, the component which has the SCF expression rise inhibitory effect confirmed for the first time by this inventor is contained in the licorice leaf part.

甘草には、Glychyrrhiza glabra、Glychyrrhiza inflata、Glychyrrhiza uralensis、Glychyrrhiza aspera、Glychyrrhiza eurycarpa、Glychyrrhiza pallidiflora、Glychyrrhiza yunnanensis、Glychyrrhiza lepidota、Glychyrrhiza echinata、Glychyrrhiza acanthocarpa等、様々な種類のものがあり、これらのうち、いずれの種類の甘草の葉部を抽出原料として使用してもよいが、特にGlychyrrhiza glabraの甘草の葉部を抽出原料として使用することが好ましい。   Licorice includes Glychyrrhiza glabra, Glychyrrhiza inflata, Glychyrrhiza uralensis, Glychyrrhiza aspera, Glychyrrhiza eurycarpa, Glychyrrhiza pallidiflora, Glychyrrhiza yunnanensis, Glychyrrhiza lepidchy, Glychyrrhly The licorice leaf part may be used as the extraction raw material, but it is particularly preferable to use the licorice leaf part of Glychyrrhiza glabra as the extraction raw material.

オニイチゴ(学名:Rubus ellipticus,中国名:切頭懸鉤子,別名:キミノヒマラヤキイチゴ)は、バラ科キイチゴ属に属する常緑低木であり、新鮮な果実は香りがあり、食用にされている。オニイチゴは、ヒマラヤから東南アジア、中国東南部で自生し又は栽培されており、これらの地域から容易に入手することができる。抽出原料として使用し得る部位としては、例えば、葉部、幹部、地上部、花部、果実部、種子部、根部、全草又はこれらの部位の混合物等が挙げられるが、好ましくは根部である。   Oni strawberry (scientific name: Rubus ellipticus, Chinese name: Kurikage Kyoko, aka: Kimino Himalayan strawberry) is an evergreen shrub belonging to the genus Rosaiaceae, and its fresh fruit is fragrant and edible. Oni strawberry is native or cultivated in the Southeast Asia and Southeast China from the Himalayas, and can be easily obtained from these regions. Examples of a part that can be used as an extraction raw material include a leaf part, a stem part, an above-ground part, a flower part, a fruit part, a seed part, a root part, a whole plant, or a mixture of these parts, but preferably a root part. .

ビワ(学名:Eriobotrya japonica Lindley)は、バラ科ビワ属に属する常緑高木であり、中国南西部原産であり、長崎、千葉、鹿児島等で栽培されており、これらの地域から容易に入手することができる。抽出原料として使用し得る部位としては、例えば、葉部、幹部、枝部、花部、果実部、種子部、根部又はこれらの部位の混合物等が挙げられるが、好ましくは葉部である。ビワの葉部は、「名医別録」に収載され、古くから薬草として用いられてきた。葉の形が琵琶に似ているからその名が付いたといわれている。日本では江戸時代にこのビワの葉の毛を除去して乾燥したものを主剤とした煎じ薬を「枇杷薬湯」と称し、暑気払いに用いていた。   Biwa (scientific name: Eriobotrya japonica Lindley) is an evergreen tree belonging to the genus Biwa of the family Rosaceae, native to the southwestern part of China, and cultivated in Nagasaki, Chiba, Kagoshima, etc., and can be easily obtained from these areas it can. Examples of the part that can be used as the extraction raw material include a leaf part, a trunk part, a branch part, a flower part, a fruit part, a seed part, a root part, or a mixture of these parts, and a leaf part is preferable. The loquat of loquat is listed in the “Special Medical Supplement” and has long been used as a medicinal herb. It is said that the name is given because the shape of the leaf resembles a camellia. In Japan, in the Edo period, the decoction that was made by removing the loquat leaves and drying them was called “Yakuyaku-yu” and was used to remove heat.

マチルス(学名:Machilus odoratissima)は、クスノキ科マチルス属に属する常緑高木であって、雲南、貴州、四川、チベット等に分布しており、これらの地域から容易に入手することができる。抽出原料として使用し得る部位としては、例えば、樹皮部、葉部、幹部、地上部、花部、果実部、種子部、根部、全草又はこれらの部位の混合物等が挙げられるが、好ましくは樹皮部である。   Machilus (scientific name: Machilus odoratissima) is an evergreen tree belonging to the genus Machilus, which is distributed in Yunnan, Guizhou, Sichuan, Tibet, etc., and can be easily obtained from these areas. Examples of the part that can be used as the raw material for extraction include bark part, leaf part, stem part, above-ground part, flower part, fruit part, seed part, root part, whole grass or a mixture of these parts, but preferably Bark.

メリッサ(学名:Melissa officinalis)は、シソ科コウスイハッカ属に属する多年生草本であり、別名としてコウスイハッカ、レモンバーム等と呼ばれている。メリッサは、地中海沿岸地方にて自生し又は栽培されている。メリッサ(Melissa)という語が、ギリシャ語のメリソフィロン(melissophyllon)、ミツバチの葉(bee leaf)に由来するように、2000年以上も前から養蜂植物として栽培され続けており、また抗アレルギー作用があることも知られている。抽出原料として使用し得る部位としては、例えば、葉部、幹部、地上部、花部、果実部、種子部、根部、全草又はこれらの部位の混合物等が挙げられるが、好ましくは全草である。   Melissa (scientific name: Melissa officinalis) is a perennial herb belonging to the genus Kosuihakka, and is also known as Kousuihakka, lemon balm, etc. Melissa is native or cultivated in the Mediterranean coast. As the word Melissa comes from the Greek words melissophyllon and bee leaf, it has been cultivated as a beekeeping plant for over 2000 years and has antiallergic effects. It is also known. Examples of a part that can be used as an extraction raw material include a leaf part, a stem part, an above-ground part, a flower part, a fruit part, a seed part, a root part, a whole plant, or a mixture of these parts. is there.

月桃(学名:Alpinia spesiosa)は、ショウガ科ハナミョウガ属に属する多年生常緑草本であり、九州南部からインドにまで分布しており、これらの地域から容易に入手することができる。月桃は、沖縄ではサンニンと呼ばれ、琉球王朝以来の伝統菓子であるムーチーに利用されるほか、ハーブとしても利用されている。抽出原料として使用し得る部位としては、例えば、葉部、幹部、地上部、花部、果実部、種子部、根部、全草又はこれらの部位の混合物等が挙げられるが、好ましくは葉部である。   Tsuki-Peach (scientific name: Alpinia spesiosa) is a perennial evergreen herb belonging to the genus Glyceraceae, and is distributed from southern Kyushu to India, and can be easily obtained from these regions. Tsuki-Peach is called Sannin in Okinawa and is used in Muchy, a traditional confectionery since the Ryukyu dynasty. Examples of the part that can be used as an extraction raw material include a leaf part, a stem part, an above-ground part, a flower part, a fruit part, a seed part, a root part, a whole plant, or a mixture of these parts. is there.

ハトムギ(学名:Coix lachrymal-jobi L.)は、中国、インドシナ地方原産の植物であって、日本では西南部の暖地で栽培されているイネ科ジュズダマ属に属する一年草であり、これらの地域から容易に入手することができる。抽出原料として使用し得る構成部位としては、例えば、葉部、枝部、樹皮部、幹部、茎部、果実部、種子部、花部、根部又はこれらの部位の混合物等が挙げられるが、好ましくは種子部である。ハトムギの種子部は特にヨクイニンと呼ばれ、利水滲湿、清熱、排膿、除痺、健脾止痛等の用途に用いられている。   The pearl barley (scientific name: Coix lachrymal-jobi L.) is a plant native to the Indochina region of China, and is an annual plant belonging to the genus Jusdama, which is cultivated in the warm southwestern part of Japan. Can be easily obtained from Examples of constituent parts that can be used as an extraction raw material include leaves, branches, bark parts, trunks, stem parts, fruit parts, seed parts, flower parts, root parts, or a mixture of these parts, but preferably Is the seed part. The seed part of pearl barley is particularly called Yokuinin, and is used for purposes such as wet water wetting, clean fever, drainage, numbness, and splenic pain.

センキュウ(学名:Ligusticum wallichii Franch.)は、中国原産の植物であって、日本では北海道、東北地方、長野、静岡、三重等で栽培されているセリ科マルバトウキ属に属する多年草であり、これらの地域から容易に入手することができる。抽出原料として使用し得る構成部位としては、例えば、葉部、枝部、樹皮部、幹部、茎部、果実部、種子部、花部、根茎部、根部又はこれらの部位の混合物等が挙げられるが、好ましくは根茎部(根部を除く)である。センキュウの根茎部(根部を除く)は、主として漢方処方薬として利用されており、婦人薬、冷え性用薬、皮膚疾患用薬、消炎背膿用薬として配合されている。   Senkyu (scientific name: Ligusticum wallichii Franch.) Is a plant native to China and is a perennial plant belonging to the genus Marbatoki which is cultivated in Hokkaido, Tohoku, Nagano, Shizuoka, Mie etc. in Japan. Can be easily obtained from Examples of constituent parts that can be used as the raw material for extraction include leaves, branches, bark parts, trunks, stem parts, fruit parts, seed parts, flower parts, rhizome parts, root parts, or a mixture of these parts. Is preferably a rhizome part (excluding the root part). The rhizome part (excluding the root part) of Senkyu is mainly used as a herbal medicine, and is formulated as a feminine medicine, a cold medicine, a skin disease medicine, and an anti-inflammatory back pus medicine.

トウニンは、バラ科サクラ属に属するモモ(学名:Prunus persica)の種子であり、中国や日本で古くから栽培されていて、これらの地域から容易に入手することができる。モモは、多くの品種が分化しており、花は観賞用として、果実は食用として利用されている。トウニンは、古くから民間薬として利用されており、浄血、鎮咳、消炎等の作用を有することが知られている。   Tounin is a seed of peach (scientific name: Prunus persica) belonging to the genus Rosaceae, and has been cultivated for a long time in China and Japan and can be easily obtained from these regions. Many varieties of peach are differentiated, flowers are used for ornamental purposes, and fruits are used for food. Tonin has been used as a folk medicine for a long time, and is known to have blood purification, antitussive, anti-inflammatory and other actions.

ゲンチアナ(学名:Gentiana Lutea)は、リンドウ科リンドウ属に属する多年生草本であり、高さ1m以上にまで達し、山地に生える多年生草本である。ゲンチアナは、ヨーロッパのアルプス山麓に自生しており、これらの地域から容易に入手することができる。抽出原料として使用し得る構成部位としては、例えば、葉部、枝部、樹皮部、幹部、茎部、果実部、種子部、花部、根茎部、根部又はこれらの部位の混合物等が挙げられるが、好ましくは根部及び根茎部である。   Gentiana (scientific name: Gentiana Lutea) is a perennial herb belonging to the genus Gentianaceae, reaching a height of more than 1 m and growing in the mountains. Gentian is native to the foothills of the Alps in Europe and is readily available from these regions. Examples of constituent parts that can be used as the raw material for extraction include leaves, branches, bark parts, trunks, stem parts, fruit parts, seed parts, flower parts, rhizome parts, root parts, or a mixture of these parts. Are preferably roots and rhizomes.

五斂子抽出物、甘草葉部抽出物、オニイチゴ抽出物、ビワ抽出物、マチルス抽出物、メリッサ抽出物、月桃抽出物、ハトムギ抽出物、センキュウ抽出物、トウニン抽出物又はゲンチアナ抽出物に含有されるSCF発現上昇抑制作用を有する物質の詳細は不明であるが、植物の抽出に一般に用いられている抽出方法によって、五斂子、甘草葉部、オニイチゴ、ビワ、マチルス、メリッサ、月桃、ハトムギ、センキュウ、トウニン又はゲンチアナからSCF発現上昇抑制作用を有する抽出物を得ることができる。   Contained in quince extract, licorice leaf extract, oni strawberry extract, loquat extract, matylus extract, melissa extract, moon peach extract, pearl barley extract, sensu extract, tonin extract or gentian extract Although the details of the SCF expression-increasing inhibitory substance are not known, depending on the extraction method generally used for the extraction of plants, five eggplants, licorice leaf part, oni strawberry, loquat, matils, melissa, moon peach, An extract having an inhibitory effect on the increase in SCF expression can be obtained from pearl barley, nematode, tonin and gentian.

例えば、上記植物を乾燥した後、そのまま又は粗砕機を用いて粉砕し、抽出溶媒による抽出に供することにより、SCF発現上昇抑制作用を有する抽出物を得ることができる。乾燥は、天日で行ってもよいし、通常使用される乾燥機を用いて行ってもよい。また、ヘキサン等の非極性溶媒によって脱脂等の前処理を施してから抽出原料として使用してもよい。脱脂等の前処理を行うことにより、上記植物の極性溶媒による抽出処理を効率よく行うことができる。   For example, after drying the plant, it is pulverized as it is or using a crusher, and subjected to extraction with an extraction solvent, whereby an extract having an SCF expression increase-inhibiting action can be obtained. Drying may be performed in the sun or may be performed using a commonly used dryer. Moreover, after performing pretreatment, such as degreasing, with a nonpolar solvent such as hexane, it may be used as an extraction raw material. By performing pretreatment such as degreasing, extraction treatment with the polar solvent of the plant can be efficiently performed.

抽出溶媒としては、極性溶媒を用いるのが好ましく、例えば、水、親水性有機溶媒等が挙げられ、これらを単独で又は2種以上を組み合わせて、室温又は溶媒の沸点以下の温度で使用することが好ましい。   As the extraction solvent, it is preferable to use a polar solvent, and examples thereof include water and hydrophilic organic solvents. These may be used alone or in combination of two or more at room temperature or a temperature below the boiling point of the solvent. Is preferred.

抽出溶媒として使用し得る水としては、純水、水道水、井戸水、鉱泉水、鉱水、温泉水、湧水、淡水等のほか、これらに各種処理を施したものが含まれる。水に施す処理としては、例えば、精製、加熱、殺菌、濾過、イオン交換、浸透圧調整、緩衝化等が含まれる。したがって、本発明において抽出溶媒として使用し得る水には、精製水、熱水、イオン交換水、生理食塩水、リン酸緩衝液、リン酸緩衝生理食塩水等も含まれる。   Examples of water that can be used as the extraction solvent include pure water, tap water, well water, mineral spring water, mineral water, hot spring water, spring water, fresh water, and the like, and those subjected to various treatments. Examples of the treatment applied to water include purification, heating, sterilization, filtration, ion exchange, osmotic pressure adjustment, buffering, and the like. Therefore, the water that can be used as the extraction solvent in the present invention includes purified water, hot water, ion-exchanged water, physiological saline, phosphate buffer, phosphate buffered saline, and the like.

抽出溶媒として使用し得る親水性有機溶媒としては、メタノール、エタノール、プロピルアルコール、イソプロピルアルコール等の炭素数1〜5の低級脂肪族アルコール;アセトン、メチルエチルケトン等の低級脂肪族ケトン;1,3−ブチレングリコール、プロピレングリコール、グリセリン等の炭素数2〜5の多価アルコール等が挙げられる。   Examples of hydrophilic organic solvents that can be used as extraction solvents include lower aliphatic alcohols having 1 to 5 carbon atoms such as methanol, ethanol, propyl alcohol, and isopropyl alcohol; lower aliphatic ketones such as acetone and methyl ethyl ketone; 1,3-butylene. Examples thereof include polyhydric alcohols having 2 to 5 carbon atoms such as glycol, propylene glycol and glycerin.

2種以上の極性溶媒の混合液を抽出溶媒として使用する場合、その混合比は適宜調整することができる。例えば、水と低級脂肪族アルコールとの混合液を使用する場合には、水10質量部に対して低級脂肪族アルコール1〜90質量部を混合することが好ましく、水と低級脂肪族ケトンとの混合液を使用する場合には、水10質量部に対して低級脂肪族ケトン1〜40質量部を混合することが好ましく、水と多価アルコールとの混合液を使用する場合には、水10質量部に対して多価アルコール10〜90質量部を混合することが好ましい。   When using the liquid mixture of 2 or more types of polar solvents as an extraction solvent, the mixing ratio can be adjusted suitably. For example, when using a liquid mixture of water and a lower aliphatic alcohol, it is preferable to mix 1 to 90 parts by weight of a lower aliphatic alcohol with respect to 10 parts by weight of water. When using a mixed solution, it is preferable to mix 1 to 40 parts by mass of a lower aliphatic ketone with 10 parts by mass of water, and when using a mixed solution of water and a polyhydric alcohol, water 10 It is preferable to mix 10-90 mass parts of polyhydric alcohol with respect to a mass part.

抽出処理は、抽出原料に含まれる可溶性成分を抽出溶媒に溶出させ得る限り特に限定はされず、常法に従って行うことができる。例えば、抽出原料の5〜15倍量(質量比)の抽出溶媒に、抽出原料を浸漬し、常温又は還流加熱下で可溶性成分を溶出させた後、濾過して抽出残渣を除去することにより抽出液を得ることができる。得られた抽出液は、該抽出液の希釈液若しくは濃縮液、該抽出液の乾燥物、又はこれらの粗精製物若しくは精製物を得るために、常法に従って希釈、濃縮、乾燥、精製等の処理を施してもよい。   The extraction treatment is not particularly limited as long as the soluble component contained in the extraction raw material can be eluted in the extraction solvent, and can be performed according to a conventional method. For example, the extraction raw material is immersed in 5 to 15 times the extraction solvent (mass ratio) of the extraction raw material, the soluble components are eluted at room temperature or under reflux, and then filtered to remove the extraction residue. A liquid can be obtained. The obtained extract is diluted, concentrated, dried, purified, etc. according to a conventional method in order to obtain a diluted or concentrated solution of the extract, a dried product of the extract, or a crude purified product or a purified product thereof. Processing may be performed.

精製は、例えば、活性炭処理、吸着樹脂処理、イオン交換樹脂処理等により行うことができる。得られた抽出液はそのままでもSCF発現上昇抑制剤の有効成分として使用することができるが、濃縮液又は乾燥物としたものの方が使用しやすい。   Purification can be performed by, for example, activated carbon treatment, adsorption resin treatment, ion exchange resin treatment, or the like. The obtained extract can be used as it is as an active ingredient of the SCF expression increase inhibitor, but a concentrated solution or a dried product is easier to use.

五斂子抽出物、甘草葉部抽出物、オニイチゴ抽出物、ビワ抽出物、マチルス抽出物、メリッサ抽出物、月桃抽出物、ハトムギ抽出物、センキュウ抽出物、トウニン抽出物又はゲンチアナ抽出物は、特有の匂いと味とを有しているため、その生理活性の低下を招かない範囲で脱色、脱臭等を目的とする精製を行うことも可能であるが、SCF発現上昇抑制剤に配合する場合には大量に使用するものではないから、未精製のままでも実用上支障はない。   Five coconut extract, licorice leaf extract, oni strawberry extract, loquat extract, matilus extract, melissa extract, moon peach extract, pearl barley extract, sensu extract, tonin extract or gentian extract Since it has a unique odor and taste, it can be purified for the purpose of decolorization, deodorization, etc. within a range that does not cause a decrease in its physiological activity. Is not used in large quantities, so there is no practical problem even if it is not purified.

以上のようにして得られる五斂子抽出物、甘草葉部抽出物、オニイチゴ抽出物、ビワ抽出物、マチルス抽出物、メリッサ抽出物、月桃抽出物、ハトムギ抽出物、センキュウ抽出物、トウニン抽出物又はゲンチアナ抽出物は、SCF発現上昇抑制作用を有しているため、その作用を利用してSCF発現上昇抑制剤の有効成分として用いることができる。   The quince extract, licorice leaf extract, oni strawberry extract, loquat extract, matylus extract, melissa extract, moon peach extract, pearl barley extract, nematode extract, tonin extract extracted as described above Since the product or the gentian extract has an SCF expression increase inhibitory action, it can be used as an active ingredient of an SCF expression increase inhibitor using the action.

また、五斂子抽出物、甘草葉部抽出物、オニイチゴ抽出物、ビワ抽出物、マチルス抽出物、メリッサ抽出物、月桃抽出物、ハトムギ抽出物、センキュウ抽出物、トウニン抽出物又はゲンチアナ抽出物は、そのSCF発現上昇抑制作用を利用して、SCFの発現上昇に起因する疾患の予防・治療剤、具体的には骨髄異形成症候群予防・治療剤、急性骨髄性白血病予防・治療剤、抗腫瘍剤等の有効成分として用いることもできる。   Also, quince extract, licorice leaf extract, oni strawberry extract, loquat extract, matylus extract, melissa extract, moon peach extract, barley extract, sensu extract, tonin extract or gentian extract Is a prophylactic / therapeutic agent for diseases caused by increased SCF expression, specifically, a myelodysplastic syndrome preventive / therapeutic agent, an acute myeloid leukemia prophylactic / therapeutic agent, It can also be used as an active ingredient such as a tumor agent.

本発明のSCF発現上昇抑制剤又はbFGF発現上昇抑制剤は、五斂子抽出物、甘草葉部抽出物、オニイチゴ抽出物、ビワ抽出物、マチルス抽出物、メリッサ抽出物、月桃抽出物、ハトムギ抽出物、センキュウ抽出物、トウニン抽出物及びゲンチアナ抽出物からなる群より選ばれる1種又は2種以上の植物抽出物のみからなるものでもよいし、五斂子抽出物、甘草葉部抽出物、オニイチゴ抽出物、ビワ抽出物、マチルス抽出物、メリッサ抽出物、月桃抽出物、ハトムギ抽出物、センキュウ抽出物、トウニン抽出物及びゲンチアナ抽出物からなる群より選ばれる1種又は2種以上の植物抽出物を製剤化したものでもよい。   The SCF expression increase inhibitor or bFGF expression increase inhibitor of the present invention includes five coconut extracts, licorice leaf extract, oni strawberry extract, loquat extract, matylus extract, melissa extract, moon peach extract, pearl barley It may consist of only one or two or more plant extracts selected from the group consisting of an extract, a nematode extract, a tonin extract and a gentian extract, or a quince extract, a licorice leaf extract, One or more plants selected from the group consisting of oni strawberry extract, loquat extract, matylus extract, melissa extract, moon peach extract, pearl barley extract, nematode extract, tonin extract and gentian extract An extract may be formulated.

五斂子抽出物、甘草葉部抽出物、オニイチゴ抽出物、ビワ抽出物、マチルス抽出物、メリッサ抽出物、月桃抽出物、ハトムギ抽出物、センキュウ抽出物、トウニン抽出物及びゲンチアナ抽出物からなる群より選ばれる1種又は2種以上の植物抽出物は、デキストリン、シクロデキストリン等の薬学的に許容し得るキャリアーその他任意の助剤を用いて、常法に従い、粉末状、顆粒状、錠剤状、液状等の任意の剤形に製剤化して提供することができる。この際、助剤としては、例えば、賦形剤、結合剤、崩壊剤、滑沢剤、安定剤、矯臭剤等を用いることができる。また、五斂子抽出物、甘草葉部抽出物、オニイチゴ抽出物、ビワ抽出物、マチルス抽出物、メリッサ抽出物、月桃抽出物、ハトムギ抽出物、センキュウ抽出物、トウニン抽出物及びゲンチアナ抽出物からなる群より選ばれる1種又は2種以上の植物抽出物は、他の組成物に配合して使用できるほか、軟膏剤、外用液剤、貼付剤等として使用することができる。   Consists of five lion extract, licorice leaf extract, oni strawberry extract, loquat extract, matylus extract, melissa extract, moon peach extract, pearl barley extract, sensu extract, tonin extract and gentian extract One or more plant extracts selected from the group are in the form of powder, granules, tablets in accordance with a conventional method using a pharmaceutically acceptable carrier such as dextrin and cyclodextrin and other optional auxiliaries. In addition, it can be formulated and provided in an arbitrary dosage form such as liquid. In this case, as an auxiliary agent, for example, an excipient, a binder, a disintegrant, a lubricant, a stabilizer, a flavoring agent and the like can be used. Also, quince extract, licorice leaf extract, oni strawberry extract, loquat extract, matylus extract, melissa extract, moon peach extract, barley extract, sensu extract, tonin extract and gentian extract One or more plant extracts selected from the group consisting of can be used in combination with other compositions, and can also be used as an ointment, an external liquid, a patch, and the like.

なお、本発明のSCF発現上昇抑制剤は、必要に応じてSCF発現上昇抑制作用を有する他の天然抽出物等を、五斂子抽出物、甘草葉部抽出物、オニイチゴ抽出物、ビワ抽出物、マチルス抽出物、メリッサ抽出物、月桃抽出物、ハトムギ抽出物、センキュウ抽出物、トウニン抽出物及びゲンチアナ抽出物からなる群より選ばれる1種又は2種以上の植物抽出物とともに配合して有効成分として用いることができる。   It should be noted that the SCF expression increase inhibitor of the present invention includes, as necessary, other natural extracts having an SCF expression increase inhibitory effect, such as a quince extract, licorice leaf part extract, oni strawberry extract, and loquat extract. , Effective in combination with one or more plant extracts selected from the group consisting of: Matils extract, Melissa extract, Moon peach extract, pearl barley extract, Sensu extract, Tonin extract and Gentian extract It can be used as a component.

本発明のSCF発現上昇抑制剤の患者に対する投与方法としては、皮下組織内投与、筋肉内投与、静脈内投与、経口投与、経皮投与等が挙げられるが、疾患の種類に応じて、その予防・治療等に好適な方法を適宜選択すればよい。また、本発明のSCF発現上昇抑制剤の投与量も、疾患の種類、重症度、患者の個人差、投与方法、投与期間等によって適宜増減すればよい。   Examples of the method for administering the SCF expression increase inhibitor of the present invention to a patient include subcutaneous tissue administration, intramuscular administration, intravenous administration, oral administration, transdermal administration, and the like. -A method suitable for treatment or the like may be appropriately selected. The dose of the SCF expression increase inhibitor of the present invention may be appropriately increased or decreased depending on the type of disease, severity, individual differences among patients, administration method, administration period, and the like.

本発明のSCF発現上昇抑制剤は、五斂子抽出物、甘草葉部抽出物、オニイチゴ抽出物、ビワ抽出物、マチルス抽出物、メリッサ抽出物、月桃抽出物、ハトムギ抽出物、センキュウ抽出物、トウニン抽出物及びゲンチアナ抽出物からなる群より選ばれる1種又は2種以上の植物抽出物が有するSCF発現上昇抑制作用を通じて、SCFの発現の上昇を抑制することができ、これにより色素細胞の増殖やメラニンの産生を抑制し、シミ、ソバカス、皮膚色素沈着症等を予防又は改善することができ、美白効果を得ることができる。   The SCF expression increase inhibitor of the present invention is a quince extract, licorice leaf extract, oni strawberry extract, loquat extract, matylus extract, melissa extract, moon peach extract, pearl barley extract, senkyu extract The increase in SCF expression can be suppressed through the SCF expression increase-inhibiting action of one or more plant extracts selected from the group consisting of Tonin extract and Gentian extract. Proliferation and production of melanin can be suppressed, spots, buckwheat, skin pigmentation and the like can be prevented or improved, and a whitening effect can be obtained.

また、五斂子抽出物、甘草葉部抽出物、オニイチゴ抽出物、ビワ抽出物、マチルス抽出物、メリッサ抽出物、月桃抽出物、ハトムギ抽出物、センキュウ抽出物、トウニン抽出物及びゲンチアナ抽出物からなる群より選ばれる1種又は2種以上の植物抽出物が有するSCF発現上昇抑制作用を通じて、骨髄芽球の異常増殖を抑制することができ、これにより骨髄異形成症候群、急性骨髄性白血病等の疾患を予防、治療又は改善することができる。   Also, quince extract, licorice leaf extract, oni strawberry extract, loquat extract, matylus extract, melissa extract, moon peach extract, barley extract, sensu extract, tonin extract and gentian extract The abnormal growth of myeloblasts can be suppressed through the SCF expression increase inhibitory action of one or more plant extracts selected from the group consisting of: myelodysplastic syndrome, acute myeloid leukemia, etc. Can be prevented, treated or ameliorated.

ただし、本発明のSCF発現上昇抑制剤は、これらの用途以外にもSCF発現上昇抑制作用を発揮することに意義のあるすべての用途に用いることができる。   However, the SCF expression increase inhibitor of the present invention can be used for all purposes that are meaningful for exhibiting the SCF expression increase suppression action in addition to these applications.

〔皮膚化粧料〕
本発明の五斂子抽出物、甘草葉部抽出物、オニイチゴ抽出物、ビワ抽出物、マチルス抽出物、メリッサ抽出物、月桃抽出物、ハトムギ抽出物、センキュウ抽出物、トウニン抽出物及びゲンチアナ抽出物からなる群より選ばれる1種又は2種以上の植物抽出物を有効成分として含有するSCF発現上昇抑制剤は、皮膚化粧料に配合して使用することができる。
[Skin cosmetic]
Penta extract of the present invention, licorice leaf extract, oni strawberry extract, loquat extract, matilus extract, melissa extract, moon peach extract, barley extract, sensu extract, tonin extract and gentian extract An SCF expression increase inhibitor containing one or more plant extracts selected from the group consisting of substances as an active ingredient can be used by blending it into a skin cosmetic.

皮膚化粧料におけるSCF発現上昇抑制剤の配合量は、皮膚化粧料の種類や抽出物の生理活性等によって適宜調整することができるが、好適な配合率は標準的な抽出物に換算して0.001〜10質量%である。   The blending amount of the SCF expression increase inhibitor in skin cosmetics can be adjusted as appropriate depending on the type of skin cosmetics, physiological activity of the extract, etc., but a suitable blending rate is 0 in terms of a standard extract. 0.001 to 10% by mass.

本発明のSCF発現上昇抑制剤を配合し得る皮膚化粧料は、本発明のSCF発現上昇抑制剤が有する作用を損なわない範囲で、必要に応じて皮膚化粧料の製造に通常使用される各種主剤及び助剤を併用することができる。   The skin cosmetics that can be blended with the SCF expression increase inhibitor of the present invention are various main ingredients that are usually used in the production of skin cosmetics as needed, as long as the effects of the SCF expression increase inhibitor of the present invention are not impaired. And auxiliary agents can be used in combination.

本発明のSCF発現上昇抑制剤とともに皮膚化粧料構成成分として併用可能なものとしては、例えば、グリセリン、コラーゲン、ヒアルロン酸及びその塩、コンドロイチン酸及びその塩、キチン、キトサン等の保湿剤;パラジメチルアミノ安息香酸アミル等の紫外線吸収剤;グリセロリン脂質、スフィンゴリン脂質等の複合脂質;β−カロチン、油溶性甘草エキス、リコカルコンA、バイカリン、バイカレイン、その他の活性酸素消去作用を有する物質;アズレン、グリチルリチン酸及びその塩類、グリチルレチン酸及びその誘導体、酸化亜鉛等の抗炎症作用物質;リボフラビン、トロフェロール、アスコルビン酸、葉酸等のビタミン及びその誘導体類;ホホバ油、ラノリン、流動パラフィン、スクワラン、イソステアリルアルコール等の油性成分;ステアリル硫酸ナトリウム、セシル硫酸ジエタノールアミン、ステアリン酸グリセリン等の界面活性剤;エリソルビン酸ナトリウム等の酸化防止剤;エチルパラベン等の防腐剤;植物ステロール類;リポプロテイン類;ビフィズス菌培養物、乳酸菌培養物、酵母抽出物、ブクリョウ抽出物等の微生物由来成分;褐藻抽出物、紅藻抽出物等の藻類抽出物;γ−オリザノール等の血行促進剤;硫黄等の抗脂漏剤;香料;アルコール;カルボキシポリマー等の増粘剤;チタンイエロー、ベニバナ、その他の着色料等が挙げられる。このように併用することで、より一般性のある製品となり、また、それにより、併用された他の有効成分との間の相乗作用が通常期待される以上の優れた効果をもたらすことがある。   Examples of components that can be used in combination with the SCF expression increase inhibitor of the present invention as a skin cosmetic component include glycerin, collagen, hyaluronic acid and its salts, chondroitinic acid and its salts, chitin, chitosan and other moisturizing agents; UV absorbers such as amyl aminobenzoate; complex lipids such as glycerophospholipid and sphingophospholipid; β-carotene, oil-soluble licorice extract, lycochalcone A, baicalin, baicalein, and other substances having an active oxygen scavenging action; azulene, glycyrrhizin Acids and salts thereof, glycyrrhetinic acid and derivatives thereof, anti-inflammatory substances such as zinc oxide; vitamins and derivatives thereof such as riboflavin, tropherol, ascorbic acid, folic acid; jojoba oil, lanolin, liquid paraffin, squalane, isostearyl alcohol Oil etc. Ingredients: surfactants such as sodium stearyl sulfate, diethanolamine cesyl sulfate, glyceryl stearate; antioxidants such as sodium erythorbate; preservatives such as ethyl paraben; plant sterols; lipoproteins; bifidobacteria cultures, lactic acid bacteria cultures , Components such as extract of yeast, yeast extract, algal extract such as brown algae extract, red algae extract; blood circulation promoter such as γ-oryzanol; anti-seborrheic agent such as sulfur; fragrance; alcohol; Thickeners such as carboxy polymers; titanium yellow, safflower, and other colorants. When used in this way, it becomes a more general product, and thereby a synergistic effect with other active ingredients used in combination may lead to a superior effect than would normally be expected.

上記皮膚化粧料は、その構成成分としてのSCF発現上昇抑制剤が有するSCF発現上昇抑制作用を通じて、色素細胞の増殖やメラニンの産生を抑制し、シミ、ソバカス、皮膚色素沈着症等を予防又は改善することができ、美白効果を得ることができる。   The above-mentioned skin cosmetics suppress the growth of pigment cells and the production of melanin through the SCF expression increase inhibitory action of the SCF expression increase inhibitor as a constituent component, thereby preventing or improving spots, buckwheat, skin pigmentation, etc. And a whitening effect can be obtained.

なお、本発明のSCF発現上昇抑制剤は、ヒトに対して好適に適用されるものであるが、それぞれの作用効果が奏される限り、ヒト以外の動物に対して適用することもできる。   The SCF expression increase inhibitor of the present invention is suitably applied to humans, but can also be applied to animals other than humans as long as each effect is exhibited.

以下、製造例、試験例及び配合例を示し、本発明を具体的に説明するが、本発明は下記の各例に何ら制限されるものではない。   Hereinafter, although a manufacture example, a test example, and a compounding example are shown and this invention is demonstrated concretely, this invention is not restrict | limited to each following example at all.

〔製造例1〕五斂子抽出物の製造
五斂子の葉部の粗砕物100gに50質量%エタノール(水とエタノールとの質量比=1:1)1000mLを加え、70℃に保温しながら2時間ゆるく攪拌した後、濾紙を用いて濾過し、五斂子の葉部からの抽出液を得た。得られた抽出液を40℃で減圧濃縮した後、減圧乾燥機で乾燥させて五斂子抽出物(試料1)を得た。得られた五斂子抽出物の収率は28.7質量%であった。
[Production Example 1] Manufacture of quince extract To 100 g of the crushed material of the coconut leaves, 1000 mL of 50% by mass ethanol (mass ratio of water to ethanol = 1: 1) was added and kept at 70 ° C. After gently stirring for 2 hours, the mixture was filtered using a filter paper to obtain an extract from the leaves of the quince. The obtained extract was concentrated under reduced pressure at 40 ° C., and then dried with a vacuum drier to obtain a pentagonal extract (sample 1). The yield of the obtained pentagonal extract was 28.7% by mass.

〔製造例2〕甘草葉部抽出物の製造
甘草の葉部の粗砕物100gに50質量%エタノール(水とエタノールとの質量比=1:1)1000mLを加え、70℃に保温しながら2時間ゆるく攪拌した後、濾紙を用いて濾過し、甘草の葉部からの抽出液を得た。得られた抽出液を40℃で減圧濃縮した後、減圧乾燥機で乾燥させて甘草葉部抽出物(試料2)を得た。得られた甘草葉部抽出物の収率は21.7質量%であった。
[Production Example 2] Production of licorice leaf extract 1000 g of 50% ethanol (mass ratio of water to ethanol = 1: 1) is added to 100 g of crushed licorice leaf, and the mixture is kept at 70 ° C. for 2 hours. After gently stirring, the mixture was filtered using a filter paper to obtain an extract from the leaves of licorice. The obtained extract was concentrated under reduced pressure at 40 ° C. and then dried with a vacuum dryer to obtain a licorice leaf part extract (sample 2). The yield of the obtained licorice leaf part extract was 21.7 mass%.

〔製造例3〕オニイチゴ抽出物の製造
オニイチゴの根部の粗砕物300gに50質量%エタノール(水とエタノールとの質量比=1:1)2000mLを加え、80℃に保温しながら3時間ゆるく攪拌した後、濾紙を用いて濾過し、オニイチゴの根部からの抽出液を得た。得られた抽出液を40℃で減圧濃縮した後、減圧乾燥機で乾燥させてオニイチゴ抽出物(試料3)を得た。得られたオニイチゴ抽出物の収率は12.1質量%であった。
[Production Example 3] Production of Onion Strawberry Extract To 300 g of onion strawberries, add 2000 mL of 50 mass% ethanol (mass ratio of water to ethanol = 1: 1) and gently agitate for 3 hours while keeping at 80 ° C. Then, it filtered using the filter paper and obtained the extract from the root part of Oni strawberry. The obtained extract was concentrated under reduced pressure at 40 ° C., and then dried with a vacuum dryer to obtain an onion strawberry extract (sample 3). The yield of the onion strawberry extract obtained was 12.1% by mass.

〔製造例4〕ビワ抽出物の製造
ビワの葉部の粗砕物100gに50質量%エタノール(水とエタノールとの質量比=1:1)2000mLを加え、70℃に保温しながら3時間ゆるく攪拌した後、濾紙を用いて濾過し、ビワの葉部からの抽出液を得た。得られた抽出液を40℃で減圧濃縮した後、減圧乾燥機で乾燥させてビワ抽出物(試料4)を得た。得られたビワ抽出物の収率は12.9質量%であった。
[Production Example 4] Production of loquat extract To 100 g of loquat leaves, 2000 mL of 50 mass% ethanol (mass ratio of water and ethanol = 1: 1) was added and stirred gently for 3 hours while keeping at 70 ° C. Then, it was filtered using a filter paper to obtain an extract from loquat leaves. The obtained extract was concentrated under reduced pressure at 40 ° C. and then dried with a vacuum dryer to obtain a loquat extract (sample 4). The yield of the obtained loquat extract was 12.9% by mass.

〔製造例5〕マチルス抽出物の製造
マチルスの樹皮部の粗砕物200gに50質量%エタノール(水とエタノールとの質量比=1:1)2000mLを加え、80℃に保温しながら2時間ゆるく攪拌した後、濾紙を用いて濾過し、マチルスの樹皮部からの抽出液を得た。得られた抽出液を40℃で減圧濃縮した後、減圧乾燥機で乾燥させてマチルス抽出物(試料5)を得た。得られたマチルス抽出物の収率は6.2質量%であった。
[Production Example 5] Manufacture of Matylus extract To 200 g of crude crushed bark of Matylus, 2000 mL of 50 mass% ethanol (mass ratio of water to ethanol = 1: 1) was added and stirred gently for 2 hours while keeping at 80 ° C. After that, it was filtered using a filter paper to obtain an extract from the bark portion of Matylus. The obtained extract was concentrated under reduced pressure at 40 ° C. and then dried with a vacuum drier to obtain a Mathilus extract (sample 5). The yield of the resulting Matylus extract was 6.2% by mass.

〔製造例6〕メリッサ抽出物の製造
メリッサの全草の粗砕物50gに50質量%エタノール(水とエタノールとの質量比=1:1)500mLを加え、70℃に保温しながら2時間ゆるく攪拌した後、濾紙を用いて濾過し、メリッサの全草からの抽出液を得た。得られた抽出液を40℃で減圧濃縮した後、減圧乾燥機で乾燥させてメリッサ抽出物(試料6)を得た。得られたメリッサ抽出物の収率は30.7質量%であった。
[Production Example 6] Production of Melissa extract Add 50 ml of 50% ethanol (mass ratio of water to ethanol = 1: 1) to 50 g of Melissa whole plant and gently stir for 2 hours while keeping at 70 ° C. After that, it was filtered using a filter paper to obtain an extract from Melissa whole plant. The obtained extract was concentrated under reduced pressure at 40 ° C. and then dried with a vacuum dryer to obtain a Melissa extract (sample 6). The yield of the obtained Melissa extract was 30.7% by mass.

〔製造例7〕月桃抽出物の製造
月桃の葉部の粗砕物100gに50質量%エタノール(水とエタノールとの質量比=1:1)1000mLを加え、70℃に保温しながら2時間ゆるく攪拌した後、濾紙を用いて濾過し、月桃の葉部からの抽出液を得た。得られた抽出液を40℃で減圧濃縮した後、減圧乾燥機で乾燥させて月桃抽出物(試料7)を得た。得られた月桃抽出物の収率は16.0質量%であった。
[Production Example 7] Manufacture of moon peach extract To 100 g of the crushed material of the moon peach leaf, 1000 mL of 50 mass% ethanol (mass ratio of water to ethanol = 1: 1) was added and kept at 70 ° C for 2 hours. After gently stirring, the mixture was filtered using a filter paper to obtain an extract from the leaves of moon peach. The obtained extract was concentrated under reduced pressure at 40 ° C. and then dried with a vacuum dryer to obtain a moon peach extract (sample 7). The yield of the obtained moon peach extract was 16.0 mass%.

〔製造例8〕ハトムギ抽出物の製造
ハトムギの種子部の粗砕物300gに50質量%エタノール(水とエタノールとの質量比=1:1)3000mLを加え、80℃に保温しながら2時間ゆるく攪拌した後、濾紙を用いて濾過し、ハトムギの種子部からの抽出液を得た。得られた抽出液を40℃で減圧濃縮した後、減圧乾燥機で乾燥させてハトムギ抽出物(試料8)を得た。得られたハトムギ抽出物の収率は2.0質量%であった。
[Production Example 8] Manufacture of pearl barley extract To 300 g of crushed seeds of pearl barley, 3000 mL of 50 mass% ethanol (mass ratio of water to ethanol = 1: 1) was added and gently stirred for 2 hours while keeping at 80 ° C. Then, the mixture was filtered using filter paper to obtain an extract from the seed part of pearl barley. The obtained extract was concentrated under reduced pressure at 40 ° C., and then dried with a vacuum dryer to obtain a pearl barley extract (sample 8). The yield of the obtained pearl barley extract was 2.0% by mass.

〔製造例9〕センキュウ抽出物の製造
センキュウの根茎部(根部を除く)の粗砕物100gに90質量%エタノール(水とエタノールとの質量比=1:9)500mLを加え、80℃に保温しながら2時間ゆるく攪拌した後、濾紙を用いて濾過し、センキュウの根茎部(根部を除く)からの抽出液を得た。得られた抽出液を40℃で減圧濃縮した後、減圧乾燥機で乾燥させてセンキュウ抽出物(試料9)を得た。得られたセンキュウ抽出物の収率は10.0質量%であった。
[Manufacturing Example 9] Manufacture of Senkyu Extract To 100 g of the crushed rhizome part (excluding root part), 500 mL of 90% by mass ethanol (mass ratio of water to ethanol = 1: 9) was added and kept at 80 ° C. Then, after gently stirring for 2 hours, the mixture was filtered using a filter paper to obtain an extract from the rhizome part (excluding the root part) of senkyu. The obtained extract was concentrated under reduced pressure at 40 ° C. and then dried with a vacuum drier to obtain a senkyu extract (sample 9). The yield of the resulting Senkyu extract was 10.0% by mass.

〔製造例10〕トウニン抽出物の製造
トウニンの粗砕物100gに50質量%エタノール(水とエタノールとの質量比=1:1)500mLを加え、80℃に保温しながら2時間ゆるく攪拌した後、濾紙を用いて濾過し、トウニンからの抽出液を得た。得られた抽出液を40℃で減圧濃縮した後、減圧乾燥機で乾燥させてトウニン抽出物(試料10)を得た。得られたトウニン抽出物の収率は13.3質量%であった。
[Production Example 10] Production of tonin extract 500 g of 50 mass% ethanol (mass ratio of water to ethanol = 1: 1) was added to 100 g of crude tonin, and gently stirred for 2 hours while keeping at 80 ° C. Filtration was performed using filter paper to obtain an extract from tonin. The obtained extract was concentrated under reduced pressure at 40 ° C., and then dried with a vacuum dryer to obtain a tonin extract (sample 10). The yield of the obtained tonin extract was 13.3 mass%.

〔製造例11〕ゲンチアナ抽出物の製造
ゲンチアナの根部及び根茎部の粗砕物100gにエタノール2500mLを加え、80℃に保温しながら2時間ゆるく攪拌した後、濾紙を用いて濾過し、ゲンチアナの根部及び根茎部からの抽出液を得た。得られた抽出液を40℃で減圧濃縮した後、減圧乾燥機で乾燥させてゲンチアナ抽出物(試料11)を得た。得られたゲンチアナ抽出物の収率は14.8質量%であった。
[Production Example 11] Production of gentian extract To 100 g of gentian roots and rhizomes, 2500 mL of ethanol was added and stirred gently for 2 hours while being kept at 80 ° C., followed by filtration using filter paper. An extract from the rhizome was obtained. The obtained extract was concentrated under reduced pressure at 40 ° C. and then dried with a vacuum dryer to obtain a gentian extract (sample 11). The yield of the obtained gentian extract was 14.8% by mass.

〔試験例1〕SCF mRNA発現上昇抑制作用試験
製造例1〜11で得られた各植物抽出物(試料1〜11)について、以下のようにしてSCF mRNA発現上昇抑制作用を試験した。
[Test Example 1] SCF mRNA expression increase inhibitory action test Each plant extract (samples 1 to 11) obtained in Production Examples 1 to 11 was tested for SCF mRNA expression increase suppressive action as follows.

(1)一本鎖DNAの調製
ヒト正常新生児表皮角化細胞(NHEK)を35mm dishに播種し、37℃、5%CO2−95%airの条件下にて24時間培養を行った。培養終了後、リン酸生理緩衝液1mLで洗浄し、ハンクス液1mLに交換した。これにTOREX FL20SE-30/DMRを4灯装着した紫外線照射装置を光源として、紫外線UV−Bを50mJ/cm照射した。照射後直ちに、所定濃度(表1参照)の試料(試料1〜11)添加培地に交換し、24時間培養した。培養終了後、常法により総RNAを調製した。また、「試料無添加・紫外線照射なし」及び「試料無添加・紫外線照射あり」で培養した細胞に関しても、同様に総RNAを調製した。総RNAの調製は、下記の方法を用いて行った。
(1) Preparation of single-stranded DNA Normal neonatal epidermal keratinocytes (NHEK) were seeded in a 35 mm dish and cultured under conditions of 37 ° C., 5% CO 2 -95% air for 24 hours. After completion of the culture, it was washed with 1 mL of a phosphate physiological buffer and replaced with 1 mL of Hanks' solution. Using an ultraviolet irradiation device equipped with four TOREX FL20SE-30 / DMRs as a light source, 50 mJ / cm 2 of ultraviolet rays UV-B was irradiated. Immediately after the irradiation, the medium was replaced with a medium supplemented with a sample (samples 1 to 11) having a predetermined concentration (see Table 1) and cultured for 24 hours. After completion of the culture, total RNA was prepared by a conventional method. In addition, total RNA was similarly prepared for cells cultured with “no sample added / no UV irradiation” and “no sample added / with UV irradiation”. Total RNA was prepared using the following method.

細胞を1mLのRNA抽出用試薬(製品名:ISOGEN,ニッポンジーン社製)に溶解し、クロロホルムを200μL添加後、遠心(12000回転,4℃,15分間)にて上層RNA層を単離し、さらにイソプロパノールで濃縮した。濃縮沈殿させた総RNAをTE溶液(10mM Tris-HCl/1mM EDTA,pH=8.0)に溶解して総RNA標品とし、PCR装置(製品名:TaKaRa PCR Themal Cycler MP,タカラバイオ社製)及びリアルタイムPCR専用逆転写キット(製品名:TaKaRa ExScript RT reagent Kit,タカラバイオ社製)を用いて、SCF mRNA発現量を測定するための鋳型に使用する一本鎖DNAを合成した。   Dissolve the cells in 1 mL of RNA extraction reagent (product name: ISOGEN, Nippon Gene), add 200 μL of chloroform, isolate the upper RNA layer by centrifugation (12,000 rpm, 4 ° C., 15 minutes), and further isopropanol. Concentrated with. Concentrated and precipitated total RNA was dissolved in TE solution (10 mM Tris-HCl / 1 mM EDTA, pH = 8.0) to prepare a total RNA preparation, and a PCR device (product name: TaKaRa PCR Themal Cycler MP, manufactured by Takara Bio Inc.) ) And a real-time PCR dedicated reverse transcription kit (product name: TaKaRa ExScript RT reagent Kit, manufactured by Takara Bio Inc.), single-stranded DNA used as a template for measuring the expression level of SCF mRNA was synthesized.

(2)サイバーグリーン法を用いたリアルタイム−PCR反応
SCF遺伝子増幅用プライマーとして下記の配列を有するセンスプライマー及びアンチセンスプライマーを作製した(タカラバイオ社製)。
センスプライマー:5'-cccttaggaatgacagcagtagca-3'
アンチセンスプライマー:5'-gcccttgtaagacttggctgtctc-3'
(2) Real-time-PCR reaction using the cyber green method A sense primer and an antisense primer having the following sequences were prepared as primers for SCF gene amplification (manufactured by Takara Bio Inc.).
Sense primer: 5'-cccttaggaatgacagcagtagca-3 '
Antisense primer: 5'-gcccttgtaagacttggctgtctc-3 '

また、内部標準としてのG3PDH遺伝子増幅用プライマーとして下記の配列を有するセンスプライマー及びアンチセンスプライマーを作製した(タカラバイオ社製)。
センスプライマー:5'-gcaccgtcaaggctgagaac-3'
アンチセンスプライマー:5'-atggtggtgaagacgccagt-3'
Moreover, the sense primer and antisense primer which have the following arrangement | sequence were produced as a G3PDH gene amplification primer as an internal standard (made by Takara Bio Inc.).
Sense primer: 5'-gcaccgtcaaggctgagaac-3 '
Antisense primer: 5'-atggtggtgaagacgccagt-3 '

「試料無添加・紫外線照射なし」、「試料無添加・紫外線照射あり」及び「試料添加・紫外線照射あり」でそれぞれ培養した細胞から調製した総RNA標品を基に調製した一本鎖DNA及び検量線作成用一本鎖DNA溶液を用いて、リアルタイムPCR装置(製品名:Real Time PCR System Smart Cycler II,Cepheid社製)及びリアルタイムPCRキット(製品名:SYBR Premix Ex Taq,タカラバイオ社製)でリアルタイムPCR反応を行った。なお、検量線作成用一本鎖DNA溶液は、原液濃度の相対値を便宜的に「100000」とし、以降10倍希釈を繰り返して濃度値「100000」、「10000」、「1000」、「100」及び「10」の5段階の希釈系列とした。反応は、95℃で10秒間保温の後、95℃で5秒間、57℃で20秒間の反応を45サイクル繰り返し、1サイクルごとにサイバーグリーン色素の発光量を測定した。   Single-stranded DNA prepared from total RNA preparations prepared from cells cultured in “No sample added / No UV irradiation”, “No sample added / With UV irradiation” and “Sample added / With UV irradiation”, respectively. Real-time PCR device (Product name: Real Time PCR System Smart Cycler II, manufactured by Cepheid) and Real-time PCR kit (Product name: SYBR Premix Ex Taq, manufactured by Takara Bio Inc.) A real-time PCR reaction was performed. In the single-stranded DNA solution for preparing a calibration curve, the relative value of the stock solution is set to “100,000” for convenience, and the concentration values “100,000”, “10000”, “1000”, “100” are repeatedly diluted 10 times thereafter. ”And“ 10 ”. The reaction was held at 95 ° C. for 10 seconds, followed by 45 cycles of 95 ° C. for 5 seconds and 57 ° C. for 20 seconds, and the amount of luminescence of the cyber green dye was measured for each cycle.

(3)解析
各サイクルのサイバーグリーン色素の発光量からSCF及びG3PDHのそれぞれをコードするDNA断片の増幅曲線を作成した。検量線作成用一本鎖DNA溶液の希釈系列の増幅曲線から横軸に濃度、縦軸に増幅曲線の2次導関数が最大となるサイクル数をとった検量線を作成した。各発現定量用サンプルについては、増幅曲線の2次導関数が最大となるサイクル数を検量線上にプロットし、相対的な発現量を算出した。SCFの発現量は、同一サンプルにおけるG3PDHの発現量の値で補正した後、さらに「試料無添加・紫外線照射なし」の補正値を100としたときの「試料無添加・紫外線照射あり」及び「試料添加・紫外線照射あり」の補正値として算出した。
(3) Analysis An amplification curve of a DNA fragment encoding each of SCF and G3PDH was prepared from the amount of luminescence of the cyber green dye in each cycle. A calibration curve was prepared from the amplification curve of a dilution series of a single-stranded DNA solution for preparing a calibration curve, with the horizontal axis representing the concentration and the vertical axis representing the number of cycles that maximized the second derivative of the amplification curve. For each expression quantification sample, the number of cycles that maximized the second derivative of the amplification curve was plotted on a calibration curve, and the relative expression level was calculated. After correcting the expression level of SCF with the value of the expression level of G3PDH in the same sample, when the correction value of “no sample added / no UV irradiation” is set to 100, “no sample added / UV irradiation” and “ It was calculated as a correction value for “sample addition / with UV irradiation”.

SCF mRNA発現上昇率(%)は下記式により算出した。
mRNA発現上昇抑制率(%)={(A−B)−(A−C)}/(A−B)×100
式中、Aは「試料無添加・紫外線照射なしの補正値」を表し、Bは、「試料無添加・紫外線照射ありの補正値」を表し、Cは、「試料添加・紫外線照射ありの補正値」を表す。
SCF mRNA発現上昇抑制作用試験の結果を表1に示す。
The SCF mRNA expression increase rate (%) was calculated by the following formula.
mRNA expression increase suppression rate (%) = {(AB) − (AC)} / (AB) × 100
In the formula, A represents “correction value without sample addition / ultraviolet irradiation”, B represents “correction value without sample addition / ultraviolet irradiation”, and C represents “correction value with sample addition / ultraviolet irradiation”. Value ".
The results of the SCF mRNA expression increase inhibitory action test are shown in Table 1.

Figure 2008273875
Figure 2008273875

表1に示すように、五斂子抽出物、甘草葉部抽出物、オニイチゴ抽出物、ビワ抽出物、マチルス抽出物、メリッサ抽出物、月桃抽出物、ハトムギ抽出物、センキュウ抽出物、トウニン抽出物及びゲンチアナ抽出物は、優れたSCF mRNA発現上昇抑制作用を有することが確認された。   As shown in Table 1, five coconut extract, licorice leaf extract, oni strawberry extract, loquat extract, matylus extract, melissa extract, moon peach extract, pearl extract, sensu extract, tonin extract It was confirmed that the product and the gentian extract have an excellent inhibitory effect on the increase in SCF mRNA expression.

〔配合例1〕
下記組成の乳液を常法により製造した。
五斂子葉部50質量%エタノール抽出物(製造例1) 0.01g
ホホバオイル 4.0g
プラセンタエキス 0.1g
オリーブオイル 2.0g
スクワラン 2.0g
セタノール 2.0g
モノステアリン酸グリセリル 2.0g
ポリオキシエチレンセチルエーテル(20E.0) 2.5g
オレイン酸ポリオキシエチレンソルビタン(20E.0) 2.0g
グリチルレチン酸ステアリル 0.1g
1,3−ブチレングリコール 3.0g
ヒノキチオール 0.15g
香料 0.05g
精製水 残部(全量を100gとする)
[Formulation Example 1]
An emulsion having the following composition was produced by a conventional method.
Pentagram 50% by weight ethanol extract (Production Example 1) 0.01 g
Jojoba oil 4.0g
Placenta extract 0.1g
Olive oil 2.0g
Squalane 2.0g
Cetanol 2.0g
Glyceryl monostearate 2.0g
2.5 g of polyoxyethylene cetyl ether (20E.0)
Oleic acid polyoxyethylene sorbitan (20E.0) 2.0 g
Stearyl glycyrrhetinate 0.1g
1,3-butylene glycol 3.0 g
Hinokitiol 0.15g
Fragrance 0.05g
Purified water remainder (total amount is 100 g)

〔配合例2〕
下記組成の化粧水を常法により製造した。
ビワ葉部50質量%エタノール抽出物(製造例1) 2g
グリセリン 3g
1,3−ブチレングリコール 3g
オレイン酸ポリオキシエチレンソルビタン(20E.0) 0.5g
パラオキシ安息香酸メチル 0.15g
クエン酸 0.1g
クエン酸ソーダ 0.1g
香料 0.05g
精製水 残部(全量を100gとする)
[Formulation Example 2]
A lotion having the following composition was produced by a conventional method.
Loquat leaf 50% by weight ethanol extract (Production Example 1) 2g
Glycerin 3g
1,3-butylene glycol 3g
Oleic acid polyoxyethylene sorbitan (20E.0) 0.5g
Methyl paraoxybenzoate 0.15g
Citric acid 0.1g
Sodium citrate 0.1g
Fragrance 0.05g
Purified water remainder (total amount is 100 g)

〔配合例3〕
下記組成のクリームを常法により製造した。
マチルス樹皮部50質量%エタノール抽出物(製造例5) 0.05g
アロエエキス 0.1g
流動パラフィン 5.0g
サラシミツロウ 4.0g
スクワラン 10.0g
セタノール 3.0g
ラノリン 2.0g
ステアリン酸 1.0g
オレイン酸ポリオキシエチレンソルビタン(20E.0) 1.5g
モノステアリン酸グリセリル 3.0g
油溶性甘草エキス 0.1g
1,3−ブチレングリコール 6.0g
パラオキシ安息香酸メチル 1.5g
香料 0.1g
精製水 残部(全量を100gとする)
[Composition Example 3]
A cream having the following composition was produced by a conventional method.
50% by weight ethanol extract of Matylus bark (Production Example 5) 0.05g
Aloe extract 0.1g
Liquid paraffin 5.0g
Salami beeswax 4.0g
Squalane 10.0g
Cetanol 3.0g
Lanolin 2.0g
Stearic acid 1.0g
Oleic acid polyoxyethylene sorbitan (20E.0) 1.5g
3.0 g glyceryl monostearate
Oil soluble licorice extract 0.1g
1,3-butylene glycol 6.0 g
1.5 g of methyl paraoxybenzoate
Fragrance 0.1g
Purified water remainder (total amount is 100 g)

〔配合例4〕
下記組成のパックを常法により製造した。
メリッサ全草50質量%エタノール抽出物(製造例6) 0.05g
ヨクイニンエキス 0.1g
ポリビニルアルコール 15g
ポリエチレングリコール 3g
プロピレングリコール 7g
エタノール 10g
パラオキシ安息香酸メチル 0.05g
グリチルリチン酸ジカリウム 0.1g
香料 0.05g
精製水 残部(全量を100gとする)
[Formulation Example 4]
A pack having the following composition was produced by a conventional method.
Melissa whole plant 50 mass% ethanol extract (Production Example 6) 0.05 g
Yokuinin extract 0.1g
Polyvinyl alcohol 15g
Polyethylene glycol 3g
7g of propylene glycol
Ethanol 10g
0.05 g of methyl paraoxybenzoate
0.1g dipotassium glycyrrhizinate
Fragrance 0.05g
Purified water remainder (total amount is 100 g)

本発明の幹細胞増殖因子(SCF)発現上昇抑制剤は、日焼け後の皮膚色素沈着症、シミ、ソバカス等の予防又は改善に有用である。また、本発明の幹細胞増殖因子(SCF)発現上昇抑制剤は、骨髄異形成症候群、急性骨髄性白血病等の予防又は治療に有用である。   The stem cell growth factor (SCF) expression increase inhibitor of the present invention is useful for the prevention or improvement of skin pigmentation, sun spots, buckwheat and the like after sunburn. The stem cell growth factor (SCF) expression increase inhibitor of the present invention is useful for the prevention or treatment of myelodysplastic syndrome, acute myeloid leukemia and the like.

Claims (2)

五斂子抽出物、甘草葉部抽出物、オニイチゴ抽出物、ビワ抽出物、マチルス抽出物、メリッサ抽出物、月桃抽出物、ハトムギ抽出物、センキュウ抽出物、トウニン抽出物及びゲンチアナ抽出物からなる群より選ばれる1種又は2種以上の植物抽出物を有効成分として含有することを特徴とする幹細胞増殖因子(SCF)発現上昇抑制剤。   Consists of five lion extract, licorice leaf extract, oni strawberry extract, loquat extract, matylus extract, melissa extract, moon peach extract, pearl barley extract, sensu extract, tonin extract and gentian extract A stem cell growth factor (SCF) expression increase inhibitor comprising one or more plant extracts selected from the group as an active ingredient. 五斂子抽出物、甘草葉部抽出物、オニイチゴ抽出物、ビワ抽出物、マチルス抽出物、メリッサ抽出物、月桃抽出物、ハトムギ抽出物、センキュウ抽出物、トウニン抽出物及びゲンチアナ抽出物からなる群より選ばれる1種又は2種以上の植物抽出物を有効成分として含有することを特徴とする幹細胞増殖因子(SCF)の発現上昇に起因する疾患の予防・治療剤。   Consists of five lion extract, licorice leaf extract, oni strawberry extract, loquat extract, matylus extract, melissa extract, moon peach extract, pearl barley extract, sensu extract, tonin extract and gentian extract A prophylactic / therapeutic agent for diseases caused by increased expression of stem cell growth factor (SCF), comprising one or more plant extracts selected from the group as an active ingredient.
JP2007119579A 2007-04-27 2007-04-27 Stem cell growth factor expression increase inhibitor Active JP5137457B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007119579A JP5137457B2 (en) 2007-04-27 2007-04-27 Stem cell growth factor expression increase inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007119579A JP5137457B2 (en) 2007-04-27 2007-04-27 Stem cell growth factor expression increase inhibitor

Publications (2)

Publication Number Publication Date
JP2008273875A true JP2008273875A (en) 2008-11-13
JP5137457B2 JP5137457B2 (en) 2013-02-06

Family

ID=40052332

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007119579A Active JP5137457B2 (en) 2007-04-27 2007-04-27 Stem cell growth factor expression increase inhibitor

Country Status (1)

Country Link
JP (1) JP5137457B2 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010168337A (en) * 2008-12-22 2010-08-05 Pola Chem Ind Inc External preparation for skin containing hydroxycarboxylic acid derivative
JP2010184967A (en) * 2009-02-10 2010-08-26 Maruzen Pharmaceut Co Ltd Skin cosmetic and food and drink
JP2010215571A (en) * 2009-03-17 2010-09-30 Maruzen Pharmaceut Co Ltd ENDOTHELIN-1 mRNA EXPRESSION INCREASE INHIBITOR, BASIC FIBROBLAST CELL PROLIFERATION FACTOR mRNA EXPRESSION INCREASE INHIBITOR AND PRO-OPIOMELANOCORTIN mRNA EXPRESSION INCREASE INHIBITOR
JP2011068572A (en) * 2009-09-24 2011-04-07 Pola Chemical Industries Inc Phagocytosis inhibitor
JP2012219021A (en) * 2011-04-05 2012-11-12 Maruzen Pharmaceut Co Ltd Melanin production inhibitor
JP2013203700A (en) * 2012-03-28 2013-10-07 Mandom Corp Body odor inhibitor
KR101370113B1 (en) 2011-05-27 2014-03-04 김안나 Cosmetics Compositions for Skin-lightening comprising Extracts of Eriobotrya japonica Lindl. Leaf
JP2014136691A (en) * 2013-01-17 2014-07-28 Bio System Consulting:Kk Enzyme activity inhibitor
JP2014210723A (en) * 2013-04-18 2014-11-13 有限会社バイオシステムコンサルティング Anti-aging composition
JP2015093848A (en) * 2013-11-12 2015-05-18 丸善製薬株式会社 Skin cosmetic and hair cosmetic

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0812565A (en) * 1994-06-29 1996-01-16 Shiseido Co Ltd Skin external preparation
JP2002302451A (en) * 2001-04-02 2002-10-18 Kao Corp Scf binding inhibitor
JP2003137801A (en) * 2001-11-05 2003-05-14 Maruzen Pharmaceut Co Ltd Collagen production promoter, collagenase inhibitor, fibroblast cell-propagating agent, skin cosmetic material and food or beverage for cosmetic use
JP2004196669A (en) * 2002-12-16 2004-07-15 Kose Corp Melanocyte proliferation inhibitor and skin care preparation for external use comprising the same
JP2004238394A (en) * 2003-01-17 2004-08-26 Kose Corp Rebound inhibitor and skin care preparation for external use containing the same
JP2004352659A (en) * 2003-05-29 2004-12-16 Shiseido Co Ltd External preparation for skin for bleaching
JP2005112793A (en) * 2003-10-08 2005-04-28 Norihide Yamaguchi Bleaching cosmetic
JP2005170830A (en) * 2003-12-10 2005-06-30 Asahi Soft Drinks Co Ltd Melanogenesis inhibiting composition
JP2006008646A (en) * 2004-06-24 2006-01-12 Eiji Yoda Cosmetic material
JP2006111545A (en) * 2004-10-13 2006-04-27 Nippon Menaade Keshohin Kk Glutathione reductase activity-enhancing agent
JP2008031095A (en) * 2006-07-28 2008-02-14 Kao Corp Scf binding inhibitor

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0812565A (en) * 1994-06-29 1996-01-16 Shiseido Co Ltd Skin external preparation
JP2002302451A (en) * 2001-04-02 2002-10-18 Kao Corp Scf binding inhibitor
JP2003137801A (en) * 2001-11-05 2003-05-14 Maruzen Pharmaceut Co Ltd Collagen production promoter, collagenase inhibitor, fibroblast cell-propagating agent, skin cosmetic material and food or beverage for cosmetic use
JP2004196669A (en) * 2002-12-16 2004-07-15 Kose Corp Melanocyte proliferation inhibitor and skin care preparation for external use comprising the same
JP2004238394A (en) * 2003-01-17 2004-08-26 Kose Corp Rebound inhibitor and skin care preparation for external use containing the same
JP2004352659A (en) * 2003-05-29 2004-12-16 Shiseido Co Ltd External preparation for skin for bleaching
JP2005112793A (en) * 2003-10-08 2005-04-28 Norihide Yamaguchi Bleaching cosmetic
JP2005170830A (en) * 2003-12-10 2005-06-30 Asahi Soft Drinks Co Ltd Melanogenesis inhibiting composition
JP2006008646A (en) * 2004-06-24 2006-01-12 Eiji Yoda Cosmetic material
JP2006111545A (en) * 2004-10-13 2006-04-27 Nippon Menaade Keshohin Kk Glutathione reductase activity-enhancing agent
JP2008031095A (en) * 2006-07-28 2008-02-14 Kao Corp Scf binding inhibitor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GAO LI ET AL, BIOL. PHARM. BULL., vol. 26(7), JPN6012041130, 2003, pages 1039 - 1041, ISSN: 0002376159 *
HACHIYA A ET AL, J. INVEST. DERMATOL, vol. 116, JPN6012041126, 2001, pages 578 - 586, ISSN: 0002298851 *
J. GRABBE ET AL, ARCH DERMATOL RES, vol. 287(1), JPN6012041123, 1994, pages 78 - 84, ISSN: 0002298850 *
VIRGINA C. BROUDY ET AL, BLOOD, vol. 80(1), JPN6012041128, 1992, pages 60 - 67, ISSN: 0002376158 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010168337A (en) * 2008-12-22 2010-08-05 Pola Chem Ind Inc External preparation for skin containing hydroxycarboxylic acid derivative
JP2010184967A (en) * 2009-02-10 2010-08-26 Maruzen Pharmaceut Co Ltd Skin cosmetic and food and drink
JP2010215571A (en) * 2009-03-17 2010-09-30 Maruzen Pharmaceut Co Ltd ENDOTHELIN-1 mRNA EXPRESSION INCREASE INHIBITOR, BASIC FIBROBLAST CELL PROLIFERATION FACTOR mRNA EXPRESSION INCREASE INHIBITOR AND PRO-OPIOMELANOCORTIN mRNA EXPRESSION INCREASE INHIBITOR
JP2011068572A (en) * 2009-09-24 2011-04-07 Pola Chemical Industries Inc Phagocytosis inhibitor
JP2012219021A (en) * 2011-04-05 2012-11-12 Maruzen Pharmaceut Co Ltd Melanin production inhibitor
KR101370113B1 (en) 2011-05-27 2014-03-04 김안나 Cosmetics Compositions for Skin-lightening comprising Extracts of Eriobotrya japonica Lindl. Leaf
JP2013203700A (en) * 2012-03-28 2013-10-07 Mandom Corp Body odor inhibitor
JP2014136691A (en) * 2013-01-17 2014-07-28 Bio System Consulting:Kk Enzyme activity inhibitor
JP2014210723A (en) * 2013-04-18 2014-11-13 有限会社バイオシステムコンサルティング Anti-aging composition
JP2015093848A (en) * 2013-11-12 2015-05-18 丸善製薬株式会社 Skin cosmetic and hair cosmetic

Also Published As

Publication number Publication date
JP5137457B2 (en) 2013-02-06

Similar Documents

Publication Publication Date Title
JP5137457B2 (en) Stem cell growth factor expression increase inhibitor
JP2009256270A (en) Insulin-like growth factor-1 expression promoting agent
KR101387308B1 (en) Skin whitening composition by using of dendropanax morbifera ferment extract
KR20090055309A (en) A cosmetic composition for skin whitening and treating wrinkles
JP2011105644A (en) Melanin uptake inhibitor
KR101787531B1 (en) Composition for preventing hair loss comprising extracts of crude drug complex
KR20170137552A (en) Composition for improving skin condition comprising herb extracts mixture
KR101930264B1 (en) Cosmetic composition for inhibiting secretion of sebum and for improving acne symptoms containing natural complex extract
KR101397160B1 (en) Cosmetic compositon for skin-irritation alleviation with Inula britannica var. chinensis, Cynanchi Radix and Lysimachia foenum-graecum Hance
KR20120009554A (en) Cosmetic composition comprising mixed herbal extracts having anti-oxidant activity and anti-allergic activity
CN110251448A (en) A kind of cosmetic compositions containing propolis extract
KR20170137544A (en) Composition for improving skin condition comprising herb extracts mixture
KR100747415B1 (en) Composition for improving mastitis comprising herb extracts
JP2014221739A (en) Type vii collagen expression promoter
KR20180052987A (en) Cosmetic composition
KR101869763B1 (en) Composition for preventing and curing dermatophytosis
JP2011001326A (en) ENDOTHELIN-1 mRNA EXPRESSION INHIBITOR
JP2010215571A (en) ENDOTHELIN-1 mRNA EXPRESSION INCREASE INHIBITOR, BASIC FIBROBLAST CELL PROLIFERATION FACTOR mRNA EXPRESSION INCREASE INHIBITOR AND PRO-OPIOMELANOCORTIN mRNA EXPRESSION INCREASE INHIBITOR
KR101757457B1 (en) Cosmetic composition containing natural complex extract for anti-thermal skin aging and skin soothing
JP5570744B2 (en) Elastase activity inhibitor
JP5896618B2 (en) Melanin production inhibitor
KR20100092922A (en) A skin whintening cosmetic composition containing a oriental herb extracts mixture stabilized by nanoliposome
JP2011001328A (en) INHIBITOR ON INCREASE IN BASIC FIBROBLAST CELL PROLIFERATION FACTOR mRNA EXPRESSION
JP2017048155A (en) Dkk1 expression promoting agent and whitening agent
JP2010215535A (en) Melanin production-inhibiting agent

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121009

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121107

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121113

R150 Certificate of patent or registration of utility model

Ref document number: 5137457

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151122

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250